Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy in the United States. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvania.
IPO Year: 2020
Exchange: NASDAQ
Website: harmonybiosciences.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/10/2024 | Outperform | Raymond James | |
| 9/10/2024 | $56.00 | Buy | UBS |
| 6/21/2024 | $48.00 | Buy | Citigroup |
| 1/2/2024 | $30.00 | Neutral → Underperform | BofA Securities |
| 9/25/2023 | $40.00 → $31.00 | Neutral → Sell | Goldman |
| 9/7/2023 | $59.00 | Buy | Berenberg |
| 4/20/2023 | $35.00 | Neutral | BofA Securities |
| 10/14/2022 | $57.00 → $61.00 | Hold → Buy | Jefferies |
| 8/3/2022 | $57.00 | Buy → Hold | Jefferies |
| 7/13/2022 | $55.00 | Buy → Neutral | Goldman |
4 - Harmony Biosciences Holdings, Inc. (0001802665) (Issuer)
4 - Harmony Biosciences Holdings, Inc. (0001802665) (Issuer)
4 - Harmony Biosciences Holdings, Inc. (0001802665) (Issuer)
4 - Harmony Biosciences Holdings, Inc. (0001802665) (Issuer)
4 - Harmony Biosciences Holdings, Inc. (0001802665) (Issuer)
4 - Harmony Biosciences Holdings, Inc. (0001802665) (Issuer)
4 - Harmony Biosciences Holdings, Inc. (0001802665) (Issuer)
4 - Harmony Biosciences Holdings, Inc. (0001802665) (Issuer)
4 - Harmony Biosciences Holdings, Inc. (0001802665) (Issuer)
4 - Harmony Biosciences Holdings, Inc. (0001802665) (Issuer)
PLYMOUTH MEETING, Pa., Nov. 21, 2024 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY), today announced that Harmony's management team will participate in the following upcoming investor conferences: Citi's 2024 Global Healthcare Conference Location: MiamiTuesday, December 3, 2024Piper Sandler 36th Annual Healthcare Conference Location: New York CityFireside Chat: Wednesday, December 4, 2024, at 8:30 a.m., ETA webcast of the fireside chat will be available on the investor page of Harmony's website at https://ir.harmonybiosciences.com/. About Harmony BiosciencesH
PLYMOUTH MEETING, Pa., Oct. 30, 2024 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) (the "Company") today announced the pricing of the previously announced underwritten public offering of an aggregate of 8,000,000 shares of the Company's common stock, par value $0.00001 per share ("Common Stock"), by Marshman Fund Trust II and Valor IV Pharma Holdings, LLC (together, the "Selling Shareholders") at a public offering price of $31.00 per share. The Selling Shareholders have granted the underwriter a 30-day option to purchase an additional 1,200,000 shares of Common Stock from the Selling Shareholders at the public offering price, less underwriting discounts and commissions. Th
-- Oversubscribed financing brings together leading syndicate of life sciences investors -- -- Proceeds to support clinical development of first-in-class therapies for neurological disorders – BOSTON, Oct. 30, 2024 /PRNewswire/ -- Axonis Therapeutics, a biotechnology company focused on the development of novel neuromedicines, announced today the successful completion of an oversubscribed $115 million Series A financing. Proceeds from the financing will be used to advance Axonis' lead development candidate, AXN-027, through clinical proof-of-concept in patients. AXN-027 is a first-in-class oral small molecule designed to potentiate the function of KCC2, a major CNS chloride transporter essent
PLYMOUTH MEETING, Pa., Oct. 29, 2024 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) (the "Company") today announced the commencement of an underwritten public offering of up to 8,000,000 shares of the Company's common stock, par value $0.00001 per share ("Common Stock"), by Marshman Fund Trust II and Valor IV Pharma Holdings, LLC (together, the "Selling Shareholders"). The Selling Shareholders intend to grant the underwriters a 30-day option to purchase up to an additional 1,200,000 shares of Common Stock from the Selling Shareholders at the public offering price, less underwriting discounts and commissions. The Company is not offering any shares of Common Stock in the prop
WAKIX (pitolisant) Net Revenue of $186.0 Million for Third Quarter 2024; Surpassed $2B in Cumulative Net Revenue in Less Than Five Years On Track to Submit sNDA for Pitolisant in Idiopathic Hypersomnia (IH) in Q4 2024 Based on Updated Strong and Sustained Efficacy Data from Long-Term Extension Study Next-Gen Pitolisant-GR and Pitolisant-HD Programs Advance; IND for Potential Best-In-Class, Novel Orexin-2 Agonist On Track for mid-2025, Extending Leadership in Sleep/Wake Beyond 2040s Highlights Most Advanced Development Program and Proven Serotonergic (5-HT2) Mechanism of Action For EPX-100 in Rare Epilepsies; Pivotal Phase 3 Trial in Dravet Syndrome Ongoing; Phase 3 Registrational Trial in
PLYMOUTH MEETING, Pa., Oct. 16, 2024 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) today announced that it will report third quarter 2024 financial results on Tuesday, October 29, 2024, before the open of the U.S. financial markets. Harmony will host a conference call and webcast on October 29, 2024, at 8:30 a.m. ET to discuss the results. To participate in the call, please dial (800) 245-3047 (domestic) or (203) 518-9765 (international), and reference passcode HRMYQ324. It is recommended that you dial in at least 10 minutes prior to the call. The live and r
PLYMOUTH MEETING, Pa., Oct. 1, 2024 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY), will be providing a comprehensive pipeline update at its Investor Day event today, showcasing new data from its orexin-2 receptor agonist, next-generation pitolisant programs, and long-term extension data from its pitolisant program in idiopathic hypersomnia. The company will also provide program updates from its strategic acquisitions in Fragile X syndrome (FXS) and rare epilepsies, which have strengthened its late-stage development pipeline. "Harmony Biosciences has transfo
PLYMOUTH MEETING, Pa., Sept. 26, 2024 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY), will provide an overview of its robust, late-stage pipeline at an in-person Investor Day at 8:30 a.m. ET on October 1 in New York City. Members of Harmony's senior leadership team along with therapeutic area key opinion leaders will present to investors and research analysts the following: Highlights of the company's late-stage pipeline with key program updates, including:New data on pitolisant in idiopathic hypersomnia (IH) Update on pitolisant-HD development program New da
PLYMOUTH MEETING, Pa., Aug. 21, 2024 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY), today announced that Harmony's management team will participate in the following upcoming investor conferences: Wells Fargo 2024 Healthcare Conference Location: BostonFireside Chat: Thursday, September 5, 2024, at 9:30 a.m. ET2024 Cantor Global Healthcare Conference Location: New York CityFireside Chat: Tuesday, September 17, 2024, at 3:05 p.m. ETA webcast of the fireside chats will be available on the investor page of Harmony's website at https://ir.harmonybiosciences.com/.
WAKIX® (pitolisant) Net Revenue of $172.8 Million for Second Quarter 2024; ~29% Growth Year-over-Year Next Generation Pitolisant High-Dose (HD) Program Advances Based on Pilot Pharmacokinetic (PK) Data with PDUFA Date Expected in 2028 to Extend Pitolisant Franchise Beyond 2040 WAKIX Patent Upheld Again - U.S. Patent and Trademark Office (USPTO) Issues Final Denial After Two Attempts to Challenge the WAKIX Patent Received U.S. Food and Drug Administration (FDA) Approval and Launched WAKIX for the Treatment of EDS in Pediatric Patients with Narcolepsy Providing the First and Only Non-Scheduled Treatment Option On Track to Submit Supplemental New Drug Application for Pitolisant in Idiopa
SC 13G/A - Harmony Biosciences Holdings, Inc. (0001802665) (Subject)
SC 13G/A - Harmony Biosciences Holdings, Inc. (0001802665) (Subject)
SC 13G/A - Harmony Biosciences Holdings, Inc. (0001802665) (Subject)
SC 13G/A - Harmony Biosciences Holdings, Inc. (0001802665) (Subject)
SC 13G/A - Harmony Biosciences Holdings, Inc. (0001802665) (Subject)
SC 13D - Harmony Biosciences Holdings, Inc. (0001802665) (Filed by)
SC 13G/A - Harmony Biosciences Holdings, Inc. (0001802665) (Subject)
SC 13G/A - Harmony Biosciences Holdings, Inc. (0001802665) (Subject)
SC 13G/A - Harmony Biosciences Holdings, Inc. (0001802665) (Subject)
SC 13G/A - Harmony Biosciences Holdings, Inc. (0001802665) (Subject)
WAKIX (pitolisant) Net Revenue of $186.0 Million for Third Quarter 2024; Surpassed $2B in Cumulative Net Revenue in Less Than Five Years On Track to Submit sNDA for Pitolisant in Idiopathic Hypersomnia (IH) in Q4 2024 Based on Updated Strong and Sustained Efficacy Data from Long-Term Extension Study Next-Gen Pitolisant-GR and Pitolisant-HD Programs Advance; IND for Potential Best-In-Class, Novel Orexin-2 Agonist On Track for mid-2025, Extending Leadership in Sleep/Wake Beyond 2040s Highlights Most Advanced Development Program and Proven Serotonergic (5-HT2) Mechanism of Action For EPX-100 in Rare Epilepsies; Pivotal Phase 3 Trial in Dravet Syndrome Ongoing; Phase 3 Registrational Trial in
PLYMOUTH MEETING, Pa., Oct. 16, 2024 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) today announced that it will report third quarter 2024 financial results on Tuesday, October 29, 2024, before the open of the U.S. financial markets. Harmony will host a conference call and webcast on October 29, 2024, at 8:30 a.m. ET to discuss the results. To participate in the call, please dial (800) 245-3047 (domestic) or (203) 518-9765 (international), and reference passcode HRMYQ324. It is recommended that you dial in at least 10 minutes prior to the call. The live and r
WAKIX® (pitolisant) Net Revenue of $172.8 Million for Second Quarter 2024; ~29% Growth Year-over-Year Next Generation Pitolisant High-Dose (HD) Program Advances Based on Pilot Pharmacokinetic (PK) Data with PDUFA Date Expected in 2028 to Extend Pitolisant Franchise Beyond 2040 WAKIX Patent Upheld Again - U.S. Patent and Trademark Office (USPTO) Issues Final Denial After Two Attempts to Challenge the WAKIX Patent Received U.S. Food and Drug Administration (FDA) Approval and Launched WAKIX for the Treatment of EDS in Pediatric Patients with Narcolepsy Providing the First and Only Non-Scheduled Treatment Option On Track to Submit Supplemental New Drug Application for Pitolisant in Idiopa
PLYMOUTH MEETING, Pa., July 23, 2024 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) today announced that it will report second quarter 2024 financial results on Tuesday, August 6, 2024, before the open of the U.S. financial markets. Harmony will host a conference call and webcast on August 6, 2024, at 8:30 a.m. ET to discuss the results. To participate in the call, please dial (800) 225-9448 (domestic) or (203) 518-9708 (international), and reference passcode HRMYQ224. It is recommended that you dial in at least 10 minutes prior to the call. The live and repl
WAKIX® (pitolisant) Net Revenue of $154.6 Million for First Quarter 2024; ~30% Growth Year-over-Year Supplemental New Drug Application for Pitolisant in Idiopathic Hypersomnia Planned for Second Half 2024 On Track Toward Pediatric Exclusivity to Extend WAKIX Exclusivity to September 2030: Pediatric Narcolepsy sNDA PDUFA Date of June 21, 2024; PWS Phase 3 TEMPO Study Initiated in March 2024 Pitolisant Franchise Revenue Potential Extended Beyond 2040 With Next-Generation Formulations; Reports Positive Pharmacokinetic Data on Next-Generation Formulation 1 (NG1); PDUFA Expected in 2026 Strengthens Leadership Position in Sleep/Wake with Licensing of TPM-1116, a Highly Potent and Selective O
Lead Candidate, EPX-100, Holds Orphan Drug and Rare Pediatric Disease Designations EPX-100 in Pivotal Registrational Trial for Dravet Syndrome; Topline Data Expected in 2026 Plan to Initiate Phase 3 Trial for Lennox-Gastaut Syndrome in Second Half of 2024 Potential Billion Dollar Plus Market Opportunity in Rare Epilepsy PLYMOUTH MEETING, Pa., April 30, 2024 /PRNewswire/ -- Harmony Biosciences (NASDAQ:HRMY), today announced the acquisition of Epygenix Therapeutics, Inc., accelerating its growth strategy by adding a rare epilepsy franchise to its expanding late-stage pipeline of innovative CNS assets.
PLYMOUTH MEETING, Pa., April 16, 2024 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) today announced that it will report first quarter 2024 financial results on Tuesday, April 30, 2024, before the open of the U.S. financial markets. Harmony will host a conference call and live webcast on April 30, 2024, at 8:30 a.m. ET to discuss the results. To participate in the call, please dial (800) 579-2543 (domestic) or +1 (785) 424-1789 (international), and reference passcode HRMYQ124. It is recommended that you dial in at least 10 minutes prior to the call. The live
WAKIX® (pitolisant) Net Revenue of $168.4 Million for Fourth Quarter and $582.0 Million for Full Year 2023; Representing Growth of ~31% and ~33%, Respectively U.S. Food and Drug Administration (FDA) Granted Priority Review for WAKIX in Pediatric Narcolepsy; PDUFA Date of June 21, 2024 Meeting with FDA to Discuss Idiopathic Hypersomnia Development Program Scheduled for March 2024 FDA Granted Orphan Drug Designation to Pitolisant for the Treatment of Prader-Willi Syndrome; On Track to Initiate Phase 3 TEMPO Study in First Quarter 2024 2024 Net Product Revenue Projected Between $700 -$720 Million Conference Call and Webcast to be Held Today at 8:30 a.m. ET PLYMOUTH MEETING, P
PLYMOUTH MEETING, Pa., Feb. 8, 2024 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) today announced that it will report fourth quarter and full year 2023 financial results on Thursday, February 22, 2024, before the open of the U.S. financial markets. Harmony will host a conference call and live webcast on February 22, 2024, at 8:30 a.m. ET to discuss the results. To participate in the call, please dial (800) 579-2543 (domestic) or +1 (785) 424-1789 (international), and reference passcode HRMYQ423. It is recommended that you dial in at least 10 minutes prior to
Continued Strong Growth with WAKIX® (pitolisant) Net Revenue of $160.3 Million for Third Quarter 2023; Increased ~37% Year-over-Year Average Number of Patients on WAKIX Increased by ~350 Sequentially to ~5,800 for Third Quarter 2023 Remain Committed and Continue to Pursue Idiopathic Hypersomnia Indication; Next Step to Meet with FDA Informed by Review of Full Data Set Expanded and Diversified Pipeline with Acquisition of Zynerba Pharmaceuticals; Zygel™ in Pivotal Phase 3 Trial for Fragile X syndrome Repurchased ~1.4 Million Shares of Common Stock for $50 Million in Third Quarter 2023; Board of Directors Authorized New $200 Million Share Repurchase Program Conference Call and Webcast
Needham analyst Ami Fadia reiterates Harmony Biosciences (NASDAQ:HRMY) with a Buy and maintains $52 price target.
Needham analyst Ami Fadia reiterates Harmony Biosciences (NASDAQ:HRMY) with a Buy and maintains $52 price target.
Across the recent three months, 7 analysts have shared their insights on Harmony Biosciences (NASDAQ:HRMY), expressing a variety of opinions spanning from bullish to bearish. The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 5 2 0 0 0 Last 30D 1 0 0 0 0 1M Ago 0 0 0 0 0 2M Ago 2 0 0 0 0 3M Ago 2 2 0 0 0 Insights from analysts' 12-month price targets are revealed, presenting an average target of $49.71, a high estimate of $52.00, and a low estimate of $48.00. This current aver
Citigroup analyst David Hoang initiates coverage on Harmony Biosciences (NASDAQ:HRMY) with a Buy rating and announces Price Target of $48.
Harmony Biosciences (NASDAQ:HRMY) presented data from its Phase 2 signal detection study showing that pitolisant reduced excessive daytime sleepiness (EDS) and fatigue in adults with Myotonic dystrophy Type 1 (DM1).
Roy Bingham, CEO of BDSA, anticipates substantial growth in the U.S. cannabis market, projecting sales to reach nearly $46 billion by 2028. This growth would be primarily fueled by the expansion of adult-use markets and adoption of new licensed and regulated markets, both medical and recreational. Key states driving this surge include New York, New Jersey and potentially Florida and Ohio, Bingham says. Influence Of DEA Rescheduling Following the DEA's decision to reclassify cannabis to Schedule III, Bingham predicts this will open up new avenues for medical research and investment. "We expect major medical discoveries within five years," he stated, highlighting the potential for new pharm
Needham analyst Ami Fadia maintains Harmony Biosciences (NASDAQ:HRMY) with a Buy and raises the price target from $50 to $52.
8-K - Harmony Biosciences Holdings, Inc. (0001802665) (Filer)
424B7 - Harmony Biosciences Holdings, Inc. (0001802665) (Filer)
424B7 - Harmony Biosciences Holdings, Inc. (0001802665) (Filer)
10-Q - Harmony Biosciences Holdings, Inc. (0001802665) (Filer)
8-K - Harmony Biosciences Holdings, Inc. (0001802665) (Filer)
8-K - Harmony Biosciences Holdings, Inc. (0001802665) (Filer)
144 - Harmony Biosciences Holdings, Inc. (0001802665) (Subject)
8-K - Harmony Biosciences Holdings, Inc. (0001802665) (Filer)
10-Q - Harmony Biosciences Holdings, Inc. (0001802665) (Filer)
8-K - Harmony Biosciences Holdings, Inc. (0001802665) (Filer)
Raymond James resumed coverage of Harmony Biosciences with a rating of Outperform
UBS initiated coverage of Harmony Biosciences with a rating of Buy and set a new price target of $56.00
Citigroup initiated coverage of Harmony Biosciences with a rating of Buy and set a new price target of $48.00
BofA Securities downgraded Harmony Biosciences from Neutral to Underperform and set a new price target of $30.00
Goldman downgraded Harmony Biosciences from Neutral to Sell and set a new price target of $31.00 from $40.00 previously
Berenberg initiated coverage of Harmony Biosciences with a rating of Buy and set a new price target of $59.00
BofA Securities initiated coverage of Harmony Biosciences with a rating of Neutral and set a new price target of $35.00
Jefferies upgraded Harmony Biosciences from Hold to Buy and set a new price target of $61.00 from $57.00 previously
Jefferies downgraded Harmony Biosciences from Buy to Hold and set a new price target of $57.00
Goldman downgraded Harmony Biosciences from Buy to Neutral and set a new price target of $55.00
PLYMOUTH MEETING, Pa., Jan. 6, 2023 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (NASDAQ:HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced that John C. Jacobs is stepping down as President and Chief Executive Officer and a member of the Board of Directors to pursue another opportunity. The Harmony Board of Directors has named Jeffrey M. Dayno, MD, Harmony's Executive Vice President and Chief Medical Officer, as interim CEO effective immediately. Jeff Aronin, Harmony's founder and Board chairman, will continue to lead the Board of Directors as well as
PLYMOUTH MEETING, Pa., Nov. 22, 2021 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (NASDAQ:HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced the appointment of Linda Szyper to the Company's Board of Directors. Ms. Szyper brings extensive healthcare and pharmaceutical knowledge with expertise anchored in more than 30 years of experience that spans both pharmaceutical sales and marketing as well as healthcare communications services. Mos
PLYMOUTH MEETING, Pa., May 18, 2021 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (NASDAQ:HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients living with rare neurological disorders who have unmet medical needs, today announced the appointment of John C. Jacobs, President and CEO of Harmony, to the Life Sciences Pennsylvania's (LSPA) Board of Directors, effective May 6, 2021. John Jacobs' election to the board is accompanied by other leaders representing the breadth, diversity and geographic reach of LS
PLYMOUTH MEETING, Pa., March 15, 2021 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients living with rare neurological disorders who have unmet medical needs, today announced the appointment of Sandip Kapadia as Chief Financial Officer effective March 29, 2021. Mr. Kapadia is an accomplished executive with more than two decades of operational experience in leading finance operations, supporting commercialization, raising capital and providing strategic guidance within the healthcare sector. "We are very pleased to welcome Sandip to Harmony. His broad and deep f